As Previously Reported was Fennec Pharmaceuticals’s largest revenue line in fiscal 2023, bringing in $11.52M of $11.30M (102%).
| Revision of Prior Period | FY 2023 |
|---|---|
| As Previously Reported | $11.52M |
| Adjustments | -$219.00K |
| Total | $11.30M |
Fennec Pharmaceuticals brought in $11.30M from its two revenue lines in fiscal 2023, the year ended September 30, 2023. As Previously Reported was the largest at $11.52M (101.9%).
The total is net of Adjustments, which took $219.00K off revenue in fiscal 2023.
Fennec Pharmaceuticals (FENC) reports its revenue by revision of prior period. In fiscal 2023, As Previously Reported was its largest revenue line, bringing in $11.52M (101.9% of the total).
As Previously Reported was Fennec Pharmaceuticals' largest revenue line in fiscal 2023, bringing in $11.52M, or 101.9% of the $11.30M total across its two revenue lines.
Every figure comes from Fennec Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Fennec Pharmaceuticals gives it, and years follow its fiscal calendar.
Fennec Pharmaceuticals' revenue by revision of prior period goes back to fiscal 2023, with figures through fiscal 2023. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.